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Idiopathic pulmonary fibrosis (IPF) is a rare, progressive
interstitial lung disease (ILD) with a poor prognosis [1].
The treatment landscape for IPF has dramatically chan-
ged in the last years [2, 3]. In the last decade, phase III
trials have shown the efficacy of anti-fibrotic medication
on slowing down lung function decline in IPF [4–7].
Since then, post hoc analyses of these trials have tremen-
dously improved our knowledge about the efficacy of
anti-fibrotic drugs across a broad spectrum of lung func-
tion impairment, the impact of concomitant medication
on disease progression, health-related quality of life, and
potential prognostic biomarkers [8–14]. Besides, data
from open-label extension studies have informed us
about the long-term safety, side-effects and tolerability
of anti-fibrotic medication [15, 16]. Nevertheless, it
should be noted that these clinical trials included a se-
lected subgroup of patients with IPF, with relatively few
comorbidities, strict lung function criteria, and age re-
strictions [4, 5, 17].
During the last years, an increasing number of IPF dis-
ease registries have emerged in order to obtain real-
world, long-term data in a broader patient population,
complementary to clinical trials. In Europe alone, there
are over 90 individual IPF registries by now; a minority
also collects data about other ILDs [17]. Patients in
registries tend to have a slightly worse health-related
quality of life, more clinically important comorbidities,
and may have a more severely impaired lung function as
compared to patients who participated in clinical trials
[18]. Real-world registries have proved to be an import-
ant source of information regarding disease behavior,
use and long-term efficacy of anti-fibrotic medication,
mortality, prevalence and impact of comorbidities, bur-
den of disease, and various other topics [19–23]. Despite
these advances, many more essential questions remain
to be elucidated in the coming years [17].
Holtze and colleagues recently addressed a few of
these questions, by publishing a detailed characterization
of IPF treatment patterns in the United States (US),
using the Pulmonary Fibrosis Foundation Patient Regis-
try (PFF-PR) [24]. The PFF-PR is a multicenter registry
with 42 registry sites across the US, which encompasses
data about 1224 patients with IPF enrolled between
2016 and 2018 [24]. With their extensive analysis of dif-
ferent factors associated with anti-fibrotic use, the au-
thors have attempted to gain better insights in the
selection process on deciding when to start anti-fibrotic
treatment and which type. Strengths of this study in-
clude the recruitment of a large number of IPF patients
with relatively few missing data. This report is among
the first in the US to provide real-world data about pre-
scription habits of anti-fibrotic medication. Data of a
specific healthcare system could give us additional in-
sights how particular healthcare systems influence treat-
ment issues in IPF.
This study yielded some interesting findings regarding
real-world diagnosis and management of IPF in the US
[24]. Less than two-thirds (61%) of patients used an anti-
fibrotic drug at the moment of enrollment in the registry
or in the twelve months before. Not only in the US, but
also in many European countries there is still a significant
number of patients in which anti-fibrotic therapy is not
initiated, despite a confirmed diagnosis of IPF [25]. More-
over, a substantial minority (23%) of patients were using
immunosuppressive medication, which is surprising be-
cause the detrimental effects of immunosuppression in
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IPF are well-recognized [26]. Up to one fourth of patients
who used anti-fibrotic medication would not have been
eligible for clinical trial participation, highlighting the
added value of this large amount of real-world registry
data. The use of anti-fibrotic medication varied, largely de-
pending on the specific registry site. Unfortunately, a more
extensive analysis of factors explaining this variation was
hampered by insufficient statistical power. It is likely that
diagnosis and treatment patterns are dependent on local
experiences and expertise. More research is needed on
how to further increase expertise in a rare disease as IPF,
which is also revealed by this large US registry. It is clear
that in a substantial minority of patients the diagnosis of
IPF has been confirmed by an experienced multidisciplin-
ary team (MDT), however, more than half of patients have
been diagnosed without validation in an MDT. This is one
of the future challenges in the field.
Factors associated with anti-fibrotic use in the PFF-PR
registry were recent clinical trial participation, lower dif-
fusion capacity of the lung, oxygen use, and increased
time since diagnosis, suggesting that anti-fibrotic drugs
are mainly initiated in patients with more severe disease
[24]. Data from other registries have shown that the use
of anti-fibrotic drugs is associated with prolonged sur-
vival, emphasizing the importance of early treatment ini-
tiation [23, 27, 28]. However, the substantial
heterogeneity of the study population (i.e. recruitment of
both incident and prevalent patients), and lack of infor-
mation about previous medication use, precludes the au-
thors from drawing any definite conclusions about the
time from diagnosis to medication initiation. This brings
us to the lack of data granularity, which is a potential
flaw in the design of the registry. For instance, data
about indications for medication use, and information
about individual healthcare providers could not be ex-
tracted. Consequently, this leads to unfounded specula-
tions, which cannot be accurately verified. Although this
may be partly inherent to the use of a real-world regis-
try, it also depends on the selection of outcome mea-
sures, and the methods of data collection and quality
control.
In this study, Holtze et al. reported on the baseline
data of patients enrolled in the PFF-PR registry [24]. Fu-
ture longitudinal data will likely yield interesting novel
information about long-term use, side-effects and effi-
cacy of anti-fibrotic drugs in a real-world US setting.
The outcomes of the present study will hopefully help to
raise more awareness among US clinicians regarding
variations in current clinical practice and prescription
patterns, and thereby give directions for future studies
and daily care.
Even though this recently published study emphasizes
the added value of disease registries in capturing real-life
data about diagnosis, treatment and follow-up of IPF
patients, it also shows that the use of registry data poses
a number of challenges [17, 18, 24, 29]. Due to the real-
world data collection, the patient population in registries
can be very heterogeneous, and data is often collected
both retrospectively and prospectively [18]. Moreover,
although selection bias is less overt than in clinical trials,
it may still play a role. Most registries recruit patients in
ILD expert centers, but not all patients are referred to
these centers (e.g. patients with significant comorbidities,
elderly patients). The majority of ongoing registry stud-
ies are conducted in a single country; only a few Euro-
pean multinational initiatives exist to date [19, 23].
Individual registries have diverse inclusion criteria, the
method of data collection and quality control varies, and
outcome measures differ. This obviously hampers the in-
terpretation, comparison, and integration of data from
multiple registries [17, 18]. For instance, the study by
Holtze et al. attempted to compare their findings with
other international registries to analyze potential differ-
ences in prescriptions patterns across the world; how-
ever, due to differences in study design, included
outcome measures and enrollment periods, accurate
comparisons were unfortunately not possible [24].
A group of ILD experts have recently proposed an idea
to create a Europe-wide meta-registry for IPF, consisting
of multiple individual registries (ARIANE-IPF) [17]. The
availability of a meta-registry will allow for additional
(subgroup) analyses and propensity analyses, which gen-
erally require large datasets. As also shown by Holtze
et al., subgroup analysis is often hampered by the rela-
tively small sample sizes of current registries [24]. Larger
datasets may especially be of added value to enhance our
knowledge and understanding of rare events, such as
acute exacerbations [29, 30]. Finally, a Europe-wide, or
even better, global registry could also facilitate analysis
of geographical variations in care and outcomes, and dif-
ferences between healthcare systems, which will hope-
fully improve equal access to care for patients in the
near future [31]. It should however be noted that regis-
tries are currently not available in all countries; thus,
registry data might still not be completely generalizable.
Though the ARIANE-IPF meta-registry initiative yielded
much enthusiasm among different stakeholders, some
potential issues have been raised too [17]. One of the
most challenging issues is the integration of data from
different registries. In order to combine individual regis-
tries, harmonization of data and standardization of out-
come measures is crucial. Unfortunately, the best way to
do this has not been fully clarified yet. Furthermore, the
number of registries, the amount of data, and the com-
plexity of data that we collect, will probably continue to
expand in the coming years. Hence, novel technologies,
such as artificial intelligence (AI) applications (e.g. nat-
ural language processing, named-entity recognition, and
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machine learning) could possibly be of added value in
the future. For instance, AI has the potential to
recognize, extract and recode data from various sources.
Moreover, AI may be used for advanced statistical ana-
lysis of very large datasets with a wide variety of data
(“big data”). Although this may seem far away, AI appli-
cations are already studied in registries for other rare
diseases [32–34].
Other factors that should be taken into account in the
design of registry studies are legal, ethical, privacy, and
methodological issues, such as the handling of missing
data. Because of the real-world nature, missing data are
usually more common in registries than in clinical trials
[18]. New technological solutions, such as online home
monitoring applications can probably help to minimize
the amount of missing data, by increasing patient par-
ticipation in registries. Patients can be actively involved
in the collection of their own data at home, by measur-
ing physiological parameters, and online completion of
patient-reported outcome measures about health-related
quality of life, symptoms and side-effects. Patients or
healthcare providers can even be reminded if data are
missing [35]. This would not only enable more frequent
data collection, as distances can be bridged online, but
would also lower the administrative burden on registry
sites.
Ideas about the added value of registry data, current
challenges, opportunities, and future directions are sum-
marized in Fig. 1.
In conclusion, we believe that current challenges can
be overcome by increasing multi-stakeholder collabor-
ation in the next years. In that way, registry data will
continue to provide answers on clinically relevant
questions and improve our knowledge about IPF. Re-
cent phase III trials have also demonstrated the effi-
cacy of anti-fibrotic medication in non-IPF fibrotic
ILDs, which will importantly change care for this
group of patients [36, 37]. Obviously, real-world data
about anti-fibrotic medication use in this patient
group is still lacking. The collection of registry data
in a more diverse group of fibrotic ILDs, using IPF
registries as a model, will be a major opportunity to
enlighten factors associated with disease behavior in
general, gain much needed insights in disease pro-
gression, learn about the clinical use of anti-fibrotic
medication including its combination with “standard”
therapies, such as immunomodulators, and will facili-
tate comparison between different diseases.
Fig. 1 Added value, challenges, opportunities and future directions of real-world registries in IPF
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